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Background: The role of percutaneous coronary intervention (PCI) in the treatment of
multivessel coronary artery disease (CAD) is still controversial and widely discussed.
More liberal use of drug-eluting stents (DES) increased proportion of those patients
undergoing PCI procedure, raising a need for more clinical evidence. The recent reported
COMPARE II trial showed similar results of Biolimus-eluting Nobori stent (BES) and
Everolimus-eluting Xience/Promus stent (EES) at 1-year in an all comers population. We
aim to compare safety and efficacy outcomes in patients with multivessel CAD (a
pre-specified study subset) treated with BES and EES in COMPARE II trial.
Methods: COMPARE II trial is a large randomized, multicentre, non-inferiority trial with
total of 2707 patients enrolled at 12 sites across Europe, randomized in 1:2 ratio to the
treatment with BES and EES with similar 12 months dual antiplatelet therapy. Primary
endpoint was the composite of cardiac death (CD), non-fatal myocardial infarction (MI)
and target vessel revascularization (TVR).
Results: Total of 683 patients with multivessel CAD have been enrolled in COMPARE
II trial, 453 of which in BES and 230 in EES arm. There were no significant differences
in baseline characteristics such as age (64.3 vs. 63.7; p0.4), male gender (78.2% vs.
78.7%; p0.9), or presence of diabetes mellitus (23.0% vs. 25.7%; p0.4) in BES and
EES arms respectively. The lesion length and reference diameters were also similar. At 12
months, rate of CD (1.1% vs 1.3%; p1.0), MI (4.4% vs 5.7%; p0.5), target lesion
revascularization (4.2% vs 2.6%; p0.4), TVR (5.7% vs 3.9; p0.4), target lesion failure
(6.8% vs 7.4%; p0.9) and composite of CD, non-fatal MI and TVR (8.6% vs 9.1%;
p0.9) were similar in BES and EES arms, Definite and propable stent thrombosis rate
up to 12-months was also not different (1.1% in BES vs 1.3% in EES arm; p1.0).
Conclusions: Although this substudy was not powered to detect differences between the
two stents, the BES with biodegradable polymer, was found as safe and effective as the
EES even in this challenging patients population. This adds valuable evidence about
clinical outcomes with contemporary DES.
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Background: With the introduction of drug eluting stents (DES) in this decade, treatment
of patients with STEMI with these devices has emerged as a rational PCI alternative. In
spite of the unquestionable benefits of DES in terms of reduction of restenosis and TVR,
specific concerns have arisen with regard to their short- and long-term safety. We aim to
assess short- and long-term outcomes in STEMI patients treated with Nobori, DES with
biodegradable polymer.
Methods: NOBORI 2 and eNOBORI are two large, prospective, single-arm, multi-
center, registries that enrolled 3067 and 7750 patients respectively, out of which 248 and
703 were STEMI patients. All adverse events were adjudicated by an independent clinical
event committee in NOBORI 2, while adjudication in eNOBORI (including stent
thrombosis) is ongoing. The primary endpoint was Target Lesion Failure (TLF) defined
as a composite of cardiac death (CD), target vessel related myocardial infarction (MI) and
target lesion revascularization (TLR).
Results: STEMI patients were 6013y old, 79% males, 11% with prior MI, 10% with
prior PCI and 0.7% with previous cardiac surgery. Multiple vessels were treated in 19.5%
of patients. The lesions were complex (60% B2/C type) ostial (10%), calcified (26%),
contained thrombus (49%) and 4% required bifurcation treatment. Pre- and post-dilatation
were performed in 54% and 29% of lesions respectively. At 1-month, there were no MIs
observed. Total of 5 patients died because of cardiac reasons (0.9%) and one TLR (0.17%)
and one TVR (0.4%) were found. The TLF rate was 1.0%. In the cohort of patients
followed at 3-year, 2 patients suffered a cardiac death (0.8%), 10 had an MI (4.0%) and
TLF rate was 6.1%. A total of 96% of the patients were angina free. Regarding stent
thrombosis (ST), occurring up to 3 years, total of 4 cases have been detected (1.6%), out
of which 3 cases were subacute (1.2%) and one case of late ST (0.4%). There was no very
late ST detected at 3 years follow up.
Conclusions: Use of Nobori, DES with biodegradable polymer, in the treatment of
patients with STEMI was associated with favorable short- and long-term outcomes,
confirming its safety and efficacy for the treatment of this high risk patient population.
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Background: The impact on healing and clinical outcomes of the individual DES
components is still under debate. The aim of this study is to assess vascular effects
exclusive to the type of antiproliferative drug, eluted via identical biodegradable polymer
and platform stents implanted in the porcine model of coronary injury.
Methods: A total of 37 stents were implanted with 110% overstretch in coronary arteries
of 14 domestic pigs: 13 biodegradable polymer coated paclitaxel eluting stents (BP-PES:
LUC-Chopin2, Balton), 16 biodegradable polymer coated everolimus eluting stents
(BP-EES, Carlo, Balton) and 8 control bare metal stents (BMS: Chopin2). Following 30
and 90 day observation (7 animals each) control coronary angiography was performed,
animals sacrificed and stented segments harvested for histopathological evaluation.
Results: At 30 days, BP-PES most effectively limited angiographic late loss (PES:
0.150.1 vs. EES: 0.400.3 vs. BMS: 0.50.2 mm, p0.04). This findings were
confirmed with the lowest neointimal formation in BP-PES in histology expressed as
neointimal thickness (NT) (EES: 0.38 [0.3-0.4] vs. PES: 0.12 [0.1-0.2] vs. BMS: 0.35
[0.3-0.4] mm, p0.01) at a cost of significantly delayed endothelialisation (EES:100% vs.
PES:404% vs. BMS:97.55%;p0.01)and higher inflammation (EES:1 vs. PES:
2.10.3 vs. BMS:1; p0.01. At 3 months late loss was numerically lowest in everolimus
stents (EES: 0.380.3 vs. PES: 0.520.4 vs. BMS:0.510.3 mm: p0.69). When
compared to one month, neointimal proliferation stabilized in EES, with lowest NT
among groups, whereas it increased fourfold in BP-PES and 30% in BMS (EES:
0.35[0.3-0.5] vs. PES: 0.53[0.5-0.8] vs. BMS: 0.46[0.4-0.5] mm: p0.07). Endothelial-
ization was complete and inflammation low in all studied stents.
Conclusions: Different patterns of vascular response were observed emphasizing different
properties of locally delivered drug, with typical neointimal catch up phenomenon after
paclitaxel and favorable long term biocompatibility, healing and efficacy after everolimus.
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Background: Small coronary vessels (reference diameter 2.75mm) are often associ-
ated with diabetic and female patients and remain an important challenge in interventional
cardiology. We performed a pre-specified substudy on outcome in patients with small
vessel treatment within the all-comer COMPARE II trial.
Methods: COMPARE II is a multicenter prospective randomized (2:1) trial, of Nobori,
Biolimus eluting stent with biodegradable polymer (BES) and Xience/Promus, everoli-
mus eluting stent (EES) in 2707 patients (1795 BES arm: 912 EES arm) with limited in-
and exclusion criteria. Within COMPARE II study, a total of 766 patients with at least 1
small vessel (2.75 mm) were treated, of which 513 were randomized to the Nobori BES
and 253 to the Xience/Promus EES. The primary endpoint was the composite of safety
(cardiac death, non fatal myocardial infarction) and efficacy (target vessel revasculariza-
tion) at 12 months. Data were entered electronically and continuously monitored. All
adverse events were adjudicated by an independent clinical event committee.
Results: In the small vessel subpopulation baseline patient and lesion characteristics
showed no differences, except for the average lesion length 16.359.45 versus
17.449.91, respectively BES versus EES, p0,02. The mean reference vessel diameter
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was 2.670.41 (948 lesions) versus 2.660.45 (500 lesions) , respectively in the BES and
EES arm (p0.60). At 12 months follow-up, the primary endpoint was 7.0% in the BES
arm vs 7.9% in the EES arm (p0.66). In the BES and EES arm, 1.6% vs 1.6% patients
suffered cardiac death (p1.0), 3.3% vs 3.6% MI (p0.83), 4.3% vs 4.4% TVR (p1.0),
and 2.5% vs 2.0 TLR (p0.80), respectively. Definite and probable stent thrombosis rate
was 0.8% in BES and 1.6% in EES (p0.45), despite similar DAPT regimens.
Conclusions: In an all-comer population, treatment of small vessels with the biodegrad-
able polymer Nobori DES showed similar outcomes compared to the everolimus eluting
Xience/Promus stent.
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Background: The newer generation drug eluting stents (DES) have shown advantages
over first generation DES, particularly relating to long term safety. However, comparative
data for contemporary DES are still insufficient. We aim to compare safety and efficacy
between Nobori DES, eluting Biolimus A9 from an abluminal biodegradable polymer
(BES) and Xience/Promus DES eluting everolimus from a permanent polymer (EES).
Methods: COMPARE II, a prospective, randomized (2:1), controlled, multi-centre study,
enrolled 2707 patients (1795 BES arm, 912 EES arm) with limited exclusion criteria. The
primary endpoint was a composite of safety (cardiac death, non fatal myocardial
infarction-MI) and efficacy (target vessel revascularization-TVR) at 1 year. Dual anti-
platelet therapy was 12 months for both arms. The primary hypothesis was non-inferiority
of BES vs EES. Data were independently monitored and adverse events were adjudicated
by an independent clinical event committee.
Results: No significant differences were detected for any of the baseline characteristics.
The patients (74% male) were63 years old, 22% had diabetes mellitus, 20% history of
MI, 18% and 6% respectively had prior PCI or CABG. In both groups 58% of patients
were treated for acute coronary syndrome (21% for STEMI). Lesions complexity was
similar (B2/C: 63%), 14% ostial, 6% bifurcated, 20% thrombosed. Lesions were longer in
EES (17.7mm vs. 16.4mm in BES, p0.02), while mean number of stents per lesions was
similar (1.40.8). The 1 year primary endpoint was 5.2% in BES arm vs 4.8% in EES
arm, confirming the hypothesis of non-inferiority hypothesis (p0.0001). There were no
significant differences in any of the secondary endpoints: 0.8% vs 0.8% patients suffered
cardiac death, 2.8% vs 2.5% had a MI, 2.9% vs 2.2% underwent TVR, and 2.7% vs 2.2%
TLR in the BES and EES arm respectively. Definite and probable stent thrombosis rate
was 0.8% in BES and 1.0% in EES.
Conclusions: In the largest prospective randomised all-comer trial, the Nobori BES is
non-inferior compared to the Xience/Promus EES. Primary and secondary endpoints in
this real-life population were not significantly different between both stent groups, with
similar, low cardiac death and ST rates.
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Background: Despite the marked efficacy of first generation drug-eluting stents (DES)
on reducing neointimal hyperplasia (NIH), restenosis, and the need for repeat target lesion
revascularization (TLR) compared to bare metal stents, concerns regarding deliverability,
efficacy, and long-term safety,led to the development of new DES technologies. The
BioMime™ device (Meril Life Sciences Pvt. Ltd., Gujarat, India) is a novel DES system
that incorporates an ultra-thin stent platform (0,0026 strut thickness), a biodegradable
polymer and sirolimus. We report the initial human evaluation of the BioMime™ stent for
the treatment of diseased coronary vessels.
Methods: The meriT-1 trial was a prospective, non-randomized, single-arm, single center
first-in-man evaluation of the safety, feasibility and performance of the novel BioMime™
SES for the treatment of coronary lesions. Lesion criteria were single de novo stenosis
50-99% located in native vessels 2.5-3.5mm in diameter and19mm in length. Left main
and bifurcation lesions, in-stent restenosis, thrombus and total occlusion were excluded.
Clinical follow-up (FU) at 1-8-12 and 24 months, and all patients were assigned to
8-month angiographic FU. Primary endpoint was in-stent late lumen loss (LLL) at 8
months. MACE (major adverse cardiac events) was defined as cardiac death, MI and
ischemia-driven TLR.
Results: A total of 30 patients/lesions. Mean age 49.9 years, 30% diabetics, and 43% had
previous MI. By angiographic analysis, baseline median lesion length, reference diameter
and % diameter stenosis: 15.51mm [12.74;20.27], 2.94mm [2.71;3.33], and 80.5 [67.0;
90.7], respectively. Overall, 30 stents implanted (1 stent/lesion). Angiographic success-
(residual stenosis20%	 final TIMI flow grade 3) and procedural success (angiographic
success without MACE in index hospitalization) were 100%. At 8 months FU (26/30),
in-stent LLL was 0.15mm [0.09;0.33]; with no binary restenosis. Clinical FU at 12
months (30/30) showed no MACE or stent thrombosis.
Conclusions: In this first-in-human evaluation the novel BioMime™ SES had excellent
performance with high procedural success and efficacy on inhibiting NIH at 8 months.
There were no MACE or stent thrombosis up to 1 year.
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Background: New generation drug eluting stents (DES) which release everolimus or
zotarolimus have been shown to be safe and effective, but these permanent polymer DESs
are related to potential risk because of inflammatory reaction and delayed healing. In this
point, biodegradable polymer biolimus-eluting stent (BES) could enhance clinical
outcomes. The purpose of this study was to compare 1 year clinical outcome of
everolimus-eluting stent (EES), zotarolimus-eluting stent (ZES) and BES in multivessel
disease or long lesion.
Methods: Of total 3089 patients in single tertiary hospital from Jan 2008 to May 2011,
604 patients who treated with DES in multivessel (2 vessels) or long lesion (28mm)
who presented with stable or unstable angina were enrolled. Major adverse cardiovascular
event (MACE) was defined as composite endpoints of death, myocardial infarction (MI)
and revascularization through 12 month.
Results: BES, EES and ZES were implanted in 149 (24.7%), 270 (44.7%) and 185
(30.6%) patients. Demographics, past history and medications were not different among
3 groups. Total number of stents was similar (BES 2.21.0, EES 2.31.2 and ZES
2.21.3, p0.755) but there were differences in stent diameter (BES 3.030.30, EES
3.110.36, ZES 2.990.41, p0.002) and stent length (BES 45.418.7, EES 52.027.1
and ZES 52.830.2, p0.017). 1 year MACE showed no significant differences among
groups (BES 26.3%, EES 44.7%, ZES 28.9%, p0.960). There were no differences in
death, MI and revascularization.
Conclusions: In multivessel or long lesion, biodegradable polymer and permanent
polymer DES showed similar clinical outcomes at 1 year. Long-term follow-up is
warranted to discriminate clinical safety and efficacy.
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Background: Treatment of long lesions (LL) remains a challenge in interventional
cardiology, with a high propensity to restenosis. Our aim was to evaluate the clinical
outcomes of the patients with LL treated with a Nobori biolimus eluting stent (BES)
versus patients treated with an everolimus eluting stent (EES) in a real world / all-comer
situation as an substudy of COMPARE II trial.
Methods: Within the prospective, randomized, multi center COMPARE II study, a total
of 627 patients with long lesions (20 mm) were treated, of which 403 were randomized
(2:1) to the Nobori BES and 224 to the Xience EES. The primary endpoint was the
composite of safety (cardiac death, non fatal myocardial infarction) and efficacy (target
vessel revascularization) at 12 months. Data was independently monitored and all adverse
events were adjudicated by an independent clinical event committee.
Results: Baseline demographics were very similar between the two study arms: no
differences were found in risk factors except for current smoking (31.1% in BES arm vs
23.2% in EES arm; p0.05). Lesions were complex (B2/C: 77.2% vs 75.3%), with a high
incidence of moderate to severe calcification (39.4% vs 39.3%), ostial location (13.0% vs
11.3%) and thrombus present (16.8% vs 13.9%). The mean lesion length (mm) was
24.6 12.3 in the BES arm versus 25.2 12.6 in the EES arm, treated with 1.67  0.90
vs 1.57  0.80 stents per lesion, respectively. At 12 months follow-up, the primary
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